Navigation Links
Recombinant in Biological Technology

PacificGMP and USC to Collaborate on Recombinant Protein Development and Manufacturing for Phase 1 Clinical Trial

SAN DIEGO and LOS ANGELES, July 27 /PRNewswire/ -- PacificGMP, the leader in single-use bioprocessing for development and manufacturing for its client partners, and the University of Southern California (USC) announced today that they have signed an agreement whereby PacificGMP will prov...

Inspiration Biopharmaceuticals Presents Safety Data on IB1001, a Novel Recombinant Factor IX for the Treatment of Hemophilia at the International Society on Thrombosis and Haemostasis (ISTH) Annual Meeting

LAGUNA NIGUEL, Calif., July 14 /PRNewswire/ -- Inspiration Biopharmaceuticals today announced the presentation of positive preclinical safety, toxicology and preliminary pharmacokinetic data on its lead product, IB1001, a novel recombinant Factor IX product to treat patients with he...

Richter-Helm and Athera Biotechnologies Partner in Development of Recombinant Protein to Treat Cardiovascular Disease

HAMBURG, Germany and STOCKHOLM, January 21 /PRNewswire/ -- Richter-Helm BioLogics GmbH & Co. KG and Athera Biotechnologies AB have signed an agreement for the development and manufacturing of Athera's novel product for prevention of plaque rupture and athero-thrombosis through binding of t...

PharmAthene Response to DHHS Request for Proposals for Recombinant Protective Antigen Anthrax Vaccine Deemed Technically Acceptable and Within Competitive Range for Procurement Consideration

ANNAPOLIS, Md., Sept. 15 /PRNewswire-FirstCall/ -- PharmAthene, Inc. (Amex: PIP ) a biodefense company specializing in the development and commercialization of medical countermeasures against chemical and biological threats, announced today that it has received notification from the Departmen...

New Recombinant XYNTHA Now Available for Patients with Hemophilia A

COLLEGEVILLE, Pa., Sept. 8 /PRNewswire/ -- Wyeth Pharmaceuticals, a division of Wyeth (NYSE: WYE ), announced today that product shipments have begun for XYNTHA(TM) Antihemophilic Factor (Recombinant), Plasma/Albumin-Free, a new recombinant factor VIII product for both the control and prevent...

Deloitte Agrees to Acquire Recombinant Capital, A Leading Life Sciences Subscription Database and Advisory Services Firm

Transaction reinforces Deloitte's leading position in the life sciences industry NEW YORK, June 16 /PRNewswire/ -- Deloitte has announced today an agreement to acquire Recombinant Capital, Inc. (Recap), a leading life sciences subscription database and advisory s...

Renovo Announces Results of Latest Phase 2 Studies of JUVISTA(R) (Human Recombinant TGFbeta3)

BASINGSTOKE, England and PHILADELPHIA, Pennysylvania, March 3 /PRNewswire-FirstCall/ -- Shire plc (LSE: SHP)(NASDAQ: SHPGY ), the global specialty biopharmaceutical company, notes that Renovo Group plc, (LSE: RNVO) ("Renovo") has today announced the results of Renovo's latest Phase 2 studies ...

Sigma-Aldrich and MorphoSys Enter Into a Collaboration and Licensing Agreement for Recombinant Research Antibodies

AbD Serotec will use proprietary technology to generate antibodies against novel research targets provided by Sigma-Aldrich MUNICH, Germany and ST. LOUIS, Feb. 27 /PRNewswire-FirstCall/ -- Sigma-Aldrich(TM) (Nasdaq: SIAL ) and MorphoSys AG (Frankfurt Stock Exchange: MOR; Prime Stand...

STALLERGENES and Protein' eXpert Enter Into a Partnership for Producing Mites Recombinant Allergens

ANTONY, GRENOBLE France, December 13 /PRNewswire-FirstCall/ -- STALLERGENES S.A and Protein'eXpert S.A. announce they have signed a partnership agreement for developing and pharmaceutically producing mites recombinant allergens(1). The partnership is part of the STALLERGENES "Enhanced Allerg...

Baxter Adds Recombinant Protein to Specialty Therapeutics Portfolio

Agreement with Kaketsuken targets rare blood disorders DEERFIELD, Ill., Oct. 16 /PRNewswire-FirstCall/ -- Baxter International Inc. (NYSE: BAX ) today announced it has signed an agreement with Kaketsuken, the Chemo-Sero-Therapeutic Research Institute, based in Kumamoto Japan, for the...

Luciferase Reporter Gene Cells and Recombinant Luciferase Dilutions Studied with the CLIPR Luciferase Assay Kit and the LMax Microplate Luminometer (MaxLine Application Note #38)

Evelyn McGown, Ph.D. , Michael Su, M.S. and Jin Liao, M.D., Ph.D. Molecular Devices Corporation, 8/00 INTRODUCTION Luciferase from the North American firefly (Photinus pyralis) is very popular foruse in Reporter Gene Assays. The enzyme catalyzes the AT...

Cell lines expressing recombinant aequorin and a G-protein coupled receptor for functional screening

INTRODUCTION Many G-protein coupled receptors (GPCRs) trigger, upon binding of an agonist, a transient increase in intracellular calcium concentration. This variation acts as an internal secondary messenger and is an important modulator of many physiological mechanisms (revie...

Preparative SDS-PAGE Electrophoresis of a Recombinant Epstein-Barr Virus Encoded Protein and Its Application in Serodiagnostic Test Systems, Rev C

Udo Reischl and Christian Gerdes, Institute of Medical Microbiology and Hygiene, University of Regensburg, 93053 Regensburg, Germany Abstract Serodiagnosis of Epstein-Barr virus (EBV) infection is currently based on the detection of ...

Purification of Recombinant Flavonone 3beta-Hydroxylase Using Bio-Scale CHT5-1 Hydroxyapatite Column

Introduction Flavanone 3b-hydroxylase (FHT), a typical 2-oxoglutaratedependent dioxygenase, catalyzes the 3b-hydroxylation of 2S-flavanones to 2R,3R-dihydroflavonols which are intermediates in the biosynthesis of flavanoids, catechins, proanthocyanid...

Expression and Purification of Recombinant Proteins That Have Native Amino Acid Sequence

One column purification of protein with native amino acid sequence Denise L. Wyborski * John C. Bauer * Barbara McGowan * Joseph A. Sorge * Peter Vaillancourt Stratagene Cloning Systems, Inc. Stratagene has improved the Affinity protein expression and purification system by t...

Novavax Reports Second Quarter 2009 Financial Results

...tion including a facility for the Spanish government using our proprietary, recombinant VLP vaccine technology. A non-profit foundation, jointly sponsored by ROVI...ke particle (VLP) technology. The Company produces these VLP based, potent, recombinant vaccines utilizing new, and efficient manufacturing approaches. Additional ...

Novavax Announces Appointment of Frederick W. Driscoll as Vice President, Chief Financial Officer and Treasurer

...ous diseases worldwide, including H1N1, using advanced proprietary virus-like particle (VLP) technology. The company produces these VLP-based, potent, recombinant vaccines utilizing new and efficient manufacturing approaches. Additional information about Novavax is available at www.novavax.com and in the com...

PharmAthene to Host Second Quarter 2009 Conference Call and Webcast on Thursday, August 13, 2009

...velopment programs include: SparVax(TM) -- a second generation recombinant protective antigen (rPA) anthrax vaccine Third generation rPA anthrax...ity associated with exposure to chemical nerve agents RypVax(TM) -- a recombinant dual antigen vaccine for plague For more information about Ph...

Repligen Reports First Quarter Fiscal Year 2010 Financial Results

...armaceutical company focused on the development of novel therapeutics for neurological disorders. In addition, we are the world's leading supplier of recombinant Protein A, the sales of which partially fund the advancement of our development pipeline while supporting our financial stability. Repligen's corpora...

GeoVax Labs, Inc. Provides Clinical Studies Update

...cine. The Technology GeoVax's unique two component vaccine, a recombinant DNA and a recombinant modified vaccinia Ankara (MVA), is designed to stimulate both anti-HIV T ce...

DOR BioPharma Receives FDA Orphan Drug Designation for orBec(R) for the Treatment of Chronic Gastrointestinal GVHD

...nse Division, DOR is developing biomedical countermeasures pursuant to the Project BioShield Act of 2004. DOR's biodefense products in development are recombinant subunit vaccines designed to protect against the lethal effects of exposure to ricin toxin, botulinum toxin and anthrax. DOR's ricin toxin vaccine, Ri...

Novavax Announces Release Date of 2009 Second Quarter, Financial Results and Investor Conference Call

...us diseases worldwide, including H1N1, using advanced proprietary virus-like particle (VLP) technology. The Company produces these VLP based, potent, recombinant vaccines utilizing new, and efficient manufacturing approaches. Additional information about Novavax is available at www.novavax.com and in the Compa...

PharmAthene, Inc. Closes on $19.3 Million Private Placement of Convertible Notes and Common Stock Warrants

...de: SparVax(TM) - a second generation recombinant protective antigen (rPA) anthrax vaccine ...hemical nerve agents RypVax(TM) - a recombinant dual antigen vaccine for plague For ...under the HHS Request for Proposals for an Anthrax recombinant Protective Antigen (rPA) Vaccine for the Strategic...

Medicago's H1N1 pandemic vaccine candidate shows positive response in 100% of vaccinated animals after a single dose

...uring technologies. Medicago is developing VLP vaccines to protect against H5N1 pandemic influenza, using a transient expression system which produces recombinant vaccine antigens in non-transgenic plants. This technology has potential to offer advantages of speed and cost over competitive technologies. It could...

Repligen Announces Conference Call of First Quarter Fiscal Year 2010 Results

...armaceutical company focused on the development of novel therapeutics for neurological disorders. In addition, we are the world's leading supplier of recombinant Protein A, the sales of which partially fund the advancement of our development pipeline while supporting our financial stability. Repligen's corpora...

Laureate Pharma Appoints Daniel E. Leone as Vice President of Business Development

... analytical services, and regulatory support. Laureate is focused on two active segments of the biopharmaceutical industry: monoclonal antibodies and recombinant protein products. For more information, contact us at info@laureatepharma.com or visit www.laureatepharma.com . Available Topic Expert(s):...

Novavax Announces Selection of a Respiratory Syncytial Virus Vaccine Candidate for Advanced Preclinical Studies

... range of infectious diseases worldwide using advanced proprietary virus-like-particle (VLP) technology. The company produces these VLP-based, potent, recombinant vaccines utilizing new and efficient manufacturing approaches. Additional information about Novavax is available at www.novavax.com and in the compan...

Novavax Announces Appointment of John J. Trizzino as Senior Vice President, International and Government Alliances

...range of infectious diseases worldwide using advanced proprietary virus-like particle (VLP) technology. The Company produces these VLP based, potent, recombinant vaccines utilizing new, and efficient manufacturing approaches. Additional information about Novavax is available at www.novavax.com and in the Compa...

Schering-Plough Reports Financial Results for 2009 Second Quarter

...trial demonstrating that a single injection of corifollitropin alfa, first in the class of sustained follicle stimulants, achieved similar efficacy to recombinant follicle stimulating hormone (rFSH) given once daily for seven days. (Announced July 1) Extended to stage two an ongoing Phase II clinical stud...

SynCo Bio Partners Increases its Capacities by Expanding its Quality Team

...ment of the largest manufacturing site of Yamanouchi in Japan. He will now support SynCo's existing QP Rob Sprenkels, in the release of GMP batches of recombinant protein, polysaccharide and live-microbial-based bulk drug substances and final product. This addition reflects SynCo's growing client base and the so...

Novavax Announces Repayment of $5 Million of Convertible Debt

...ange of infectious diseases worldwide using advanced proprietary virus-like particle (VLP) technology. The Company produces these VLP based, potent, recombinant vaccines utilizing new, and efficient manufacturing approaches. Additional information about Novavax is available at www.novavax.com and in the Compa...

PharmAthene's 2nd Generation rPA Anthrax Vaccine, SparVax(TM), Completes FDA Regulatory Strategy Review

...lan for SparVax(TM), PharmAthene's next generation recombinant protective antigen (rPA) anthrax vaccine. In ...ax(TM) SparVax(TM) is a novel second generation recombinant protective (rPA) anthrax vaccine being developed f... SparVax(TM) - a second generation recombinant protective antigen (rPA) anthrax vaccine T...

Cadila Pharmaceuticals Launches Joint Venture With Novavax in India

... range of infectious diseases worldwide using advanced proprietary virus-like-particle (VLP) technology. The company produces these VLP-based, potent, recombinant vaccines utilizing new and efficient manufacturing approaches. The Company is currently conducting Phase 2 clinical studies of a seasonal flu vaccine...

Amylin Pharmaceuticals Announces Positive Results from Dose-Ranging Clinical Study of Pramlintide/Metreleptin Combination Treatment for Obesity

...date, approximately 8,000 individuals have received pramlintide in clinical trials, including more than 950 in obesity studies. Metreleptin (methionyl recombinant leptin; r-metHuLeptin) is an analog of human leptin, a neurohormone secreted by fat cells that plays a fundamental role in the regulation of energy me...

DOR BioPharma Announces Issuance of European Patent for its LPM(TM) Oral Drug Delivery Technology

...ly those biotechnology products derived from synthetic peptide chemistry or recombinant DNA," said Christopher J. Schaber, PhD, DOR President and CEO. "We also bel...Project BioShield Act of 2004. DOR's biodefense products in development are recombinant subunit vaccines designed to protect against the lethal effects of exposure...

Schering-Plough Announces Phase II and III Data for Corifollitropin Alfa

... follicle stimulants, achieved similar efficacy to recombinant follicle stimulating hormone (rFSH) given once dai...oing pregnancy rates with corifollitropin alfa and recombinant FSH irrespective of variations in ART procedures. ... Behr B, et al Corifollitropin alfa versus recombinant FSH treatment in controlled ovarian stimulation: e...

Spanish Government Selects Novavax's VLP Technology for Comprehensive Flu Vaccine Solution in Spain

... NVAX ) announced today its initial agreement to license its proprietary, recombinant virus-like-particle (VLP) vaccine technology to ROVI Pharmaceuticals (Madri...ke-particle (VLP) technology. The company produces these VLP-based, potent, recombinant vaccines utilizing new and efficient manufacturing approaches. VLPs are de...

DOR BioPharma Announces Publication of orBec(R) Clinical Pulmonary Data in Bone Marrow Transplantation

...nse Division, DOR is developing biomedical countermeasures pursuant to the Project BioShield Act of 2004. DOR's biodefense products in development are recombinant subunit vaccines designed to protect against the lethal effects of exposure to ricin toxin, botulinum toxin and anthrax. DOR's ricin toxin vaccine, Ri...

Mylan Announces Strategic Collaboration with Biocon to Enter the Global Generic Biologics Market

...tom research and clinical research, which deliver products and solutions to partners and customers across the globe. Biocon launched the world's first recombinant human insulin, INSUGEN(R) in November 2004 using Pichia expression and India's first indigenously produced monoclonal antibody BIOMAb-EGFR(TM). Focusi...

Novavax Appoints Stanley Erck to Board of Directors

... range of infectious diseases worldwide using advanced proprietary virus-like-particle (VLP) technology. The company produces these VLP-based, potent, recombinant vaccines utilizing new and efficient manufacturing approaches. Additional information about Novavax is available at www.novavax.com and in the co...
Other Tags
(Date:9/29/2014)... a new Food and Brand Lab pilot study, published ... in the National School Lunch Program (NSLP) by 9% ... , Chefs Move to Schools (CMTS), an initiative of ... in order to provide nutrition instruction to students and ... A CMTS event was held in an Upstate New ...
(Date:9/29/2014)... world,s needs to make cheaper and more effective ... efficient catalytic materials and processes must be developed. ... State University, is tackling this problem with the ... Science Foundation. , The nearly $1.5 million project, ... Cascade Reactions," was to Eranda Nikolla, Ph.D., assistant ...
(Date:9/29/2014)... five-year, $6 million grant for clinical research and ... of safe and effective treatments for cocaine addiction. ... Institutes of Health, National Institute on Drug Abuse, ... for Cocaine Use Disorder to oversee preclinical and ... moving forward with more expensive large-scale clinical trials. ...
Breaking Biology News(10 mins):Chefs move to schools can increase school meal participation and vegetable intake among students 2Wayne State research aims to develop new, more efficient catalytic materials 2New VCU center to target cocaine addiction 2
(Date:9/30/2014)... California (PRWEB) September 30, 2014 ... its first “crowdfunding” campaign through GoFundMe. The campaign, which ... was for a portion of the funds necessary to ... bus for the Stockton Unified School District (SUSD). The ... will provide a portion of the funds necessary for ...
(Date:9/30/2014)... Montreal, September 30, 2014 More than 23 per cent ... days. While chronic stress increases the risk of poor mental ... Some cope well, but for others especially those most ... be harmful. , Thankfully, new research from Concordia University ... stress. That,s a huge help for healthcare professionals working to ...
(Date:9/30/2014)... at the University of Pittsburgh School of Dental Medicine ... the National Institute of Dental and Craniofacial Research, part ... exploration of the genetic roots of cleft lip and ... populations in Colombia, Nigeria, the Philippines and Pennsylvania. ... the lip or palate that can form when a ...
(Date:9/30/2014)... Four scientists at Cold Spring Harbor Laboratory (CSHL) will ... new CSHL grants announced in Washington today. The CSHL ... National Institutes of Health (NIH), totaling $46 million for ... for the BRAIN Initiative. , The ... by the President in the spring of 2013. It ...
(Date:9/30/2014)... York (PRWEB) September 30, 2014 A ... U.S.-based market intelligence agency states that the global medical ... of USD 18.5 billion by the end of 2019. ... at USD 10.3 billion in 2012, will report a ... a USD 18.5 billion worth market by 2019. , ...
Breaking Medicine News(10 mins):Health News:ADOMANI Raises More Than 100,000 Dollars Through GoFundMe to Convert a School Bus 2Health News:ADOMANI Raises More Than 100,000 Dollars Through GoFundMe to Convert a School Bus 3Health News:How to predict who will suffer the most from stress 2Health News:Pitt team searches for genetic roots of cleft lip, palate 2Health News:4 Cold Spring Harbor Laboratory scientists will contribute to President Obama's BRAIN Initiative under new NIH grants 2Health News:4 Cold Spring Harbor Laboratory scientists will contribute to President Obama's BRAIN Initiative under new NIH grants 3Health News:Global Medical Imaging Reagents Market Segment up to 2019: Transparency Market Research 2Health News:Global Medical Imaging Reagents Market Segment up to 2019: Transparency Market Research 3
Other Contents